{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T13:03:25Z","timestamp":1794315805872,"version":"4.9.0"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS J"],"DOI":"10.1208\/s12248-026-01260-9","type":"journal-article","created":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T20:26:12Z","timestamp":1779222372000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Immunogenicity Assessment for siRNA Therapeutics: A Risk-Based Proposal for Event-Driven Testing"],"prefix":"10.1208","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-9881-2443","authenticated-orcid":false,"given":"An","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-9290-0696","authenticated-orcid":false,"given":"Sarah","family":"Bond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-2901-9540","authenticated-orcid":false,"given":"Valerie","family":"Clausen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-9861-2399","authenticated-orcid":false,"given":"Mu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-4735-3926","authenticated-orcid":false,"given":"Ching-Ha","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-1965-2194","authenticated-orcid":false,"given":"Joshua","family":"Zylstra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5915-4317","authenticated-orcid":false,"given":"Christine","family":"Grimaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6699-8473","authenticated-orcid":false,"given":"Michael A.","family":"Partridge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,19]]},"reference":[{"issue":"1","key":"1260_CR1","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/s41392-024-02112-8","volume":"10","author":"M Liu","year":"2025","unstructured":"Liu M, Wang Y, Zhang Y, Hu D, Tang L, Zhou B, et al. Landscape of small nucleic acidtherapeutics: moving from the bench to the clinic as next-generation medicines. Signal Transduct Target Ther. 2025;10(1):73.","journal-title":"Signal Transduct Target Ther"},{"issue":"3","key":"1260_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2020.108279","volume":"33","author":"AK Rogers","year":"2020","unstructured":"Rogers AK, Phillips CM. A small-RNA-mediated feedback loop maintains proper levels of 22G-RNAs in C. elegans. Cell Rep. 2020;33(3):108279.","journal-title":"Cell Rep"},{"key":"1260_CR3","unstructured":"US Food and Drug Administration. Guidance for Industry: Clinical pharmacology consideration for the development of oligonucleotide therapeutics. 2024.\u00a0https:\/\/www.fda.gov\/media\/159414\/download.\u00a0Accessed 02 Jan 2026."},{"key":"1260_CR4","unstructured":"US Food and Drug Administration. Guidance for Industry: Nonclinical Safety Assessment of Oligonucleotide-Based Therapeutics. 2024.\u00a0https:\/\/www.fda.gov\/media\/183496\/download.\u00a0Accessed 02 Jan 2026."},{"issue":"4","key":"1260_CR5","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1128\/MMBR.67.4.657-685.2003","volume":"67","author":"N Agrawal","year":"2003","unstructured":"Agrawal N, Dasaradhi PV, Mohmmed A, Malhotra P, Bhatnagar RK, Mukherjee SK. RNA interference: biology, mechanism, and applications. Microbiol Mol Biol Rev. 2003;67(4):657\u201385.","journal-title":"Microbiol Mol Biol Rev"},{"issue":"6","key":"1260_CR6","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1002\/cbic.201500023","volume":"16","author":"KG Rajeev","year":"2015","unstructured":"Rajeev KG, Nair JK, Jayaraman M, Charisse K, Taneja N, O\u2019Shea J, et al. Hepatocyte-specific delivery of siRNAs conjugated to novel non-nucleosidic trivalent N-acetylgalactosamine elicits robust gene silencing in vivo. Chembiochem. 2015;16(6):903\u20138.","journal-title":"Chembiochem"},{"issue":"19-20","key":"1260_CR7","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1016\/j.drudis.2008.05.007","volume":"13","author":"JK Watts","year":"2008","unstructured":"Watts JK, Deleavey GF, Damha MJ. Chemically modified siRNA: tools and applications. Drug Discov Today. 2008;13(19\u201320):842\u201355.","journal-title":"Drug Discov Today"},{"issue":"9","key":"1260_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/mtna.2015.23","volume":"4","author":"JK Lam","year":"2015","unstructured":"Lam JK, Chow MY, Zhang Y, Leung SW. siRNA versus miRNA as therapeutics for gene silencing. Mol Ther Nucleic Acids. 2015;4(9):e252.","journal-title":"Mol Ther Nucleic Acids"},{"issue":"1","key":"1260_CR9","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.antiviral.2007.12.008","volume":"78","author":"KB Spurgers","year":"2008","unstructured":"Spurgers KB, Sharkey CM, Warfield KL, Bavari S. Oligonucleotide antiviral therapeutics: antisense and RNA interference for highly pathogenic RNA viruses. Antiviral Res. 2008;78(1):26\u201336.","journal-title":"Antiviral Res"},{"issue":"3","key":"1260_CR10","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1038\/mt.2011.294","volume":"20","author":"RL Kanasty","year":"2012","unstructured":"Kanasty RL, Whitehead KA, Vegas AJ, Anderson DG. Action and reaction: the biological response to siRNA and its delivery vehicles. Mol Ther. 2012;20(3):513\u201324.","journal-title":"Mol Ther"},{"issue":"11","key":"1260_CR11","doi-asserted-by":"publisher","first-page":"2704","DOI":"10.1007\/s13346-023-01361-4","volume":"13","author":"A Kaushal","year":"2023","unstructured":"Kaushal A. Innate immune regulations and various siRNA modalities. Drug Deliv Transl Res. 2023;13(11):2704\u201318.","journal-title":"Drug Deliv Transl Res"},{"issue":"7","key":"1260_CR12","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.3109\/21691401.2015.1102738","volume":"44","author":"B Mansoori","year":"2016","unstructured":"Mansoori B, Mohammadi A, Shir Jang S, Baradaran B. Mechanisms of immune system activation in mammalians by small interfering RNA (siRNA). Artif Cells Nanomed Biotechnol. 2016;44(7):1589\u201396.","journal-title":"Artif Cells Nanomed Biotechnol"},{"issue":"5","key":"1260_CR13","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1016\/j.jmb.2005.03.013","volume":"348","author":"M Sioud","year":"2005","unstructured":"Sioud M. Induction of inflammatory cytokines and interferon responses by double-stranded and single-stranded siRNAs is sequence-dependent and requires endosomal localization. J Mol Biol. 2005;348(5):1079\u201390.","journal-title":"J Mol Biol"},{"issue":"4","key":"1260_CR14","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/nbt1081","volume":"23","author":"AD Judge","year":"2005","unstructured":"Judge AD, Sood V, Shaw JR, Fang D, McClintock K, MacLachlan I. Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. Nat Biotechnol. 2005;23(4):457\u201362.","journal-title":"Nat Biotechnol"},{"issue":"7","key":"1260_CR15","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/j.imbio.2009.09.003","volume":"215","author":"S Hamm","year":"2010","unstructured":"Hamm S, Latz E, Hangel D, Muller T, Yu P, Golenbock D, et al. Alternating 2\u2019-O-ribose methylation is a universal approach for generating non-stimulatory siRNA by acting as TLR7 antagonist. Immunobiology. 2010;215(7):559\u201369.","journal-title":"Immunobiology"},{"issue":"6","key":"1260_CR16","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1177\/21593337251387423","volume":"35","author":"J Grudzinska-Goebel","year":"2025","unstructured":"Grudzinska-Goebel J, Braun M, Chen LZ, Gupta S, Lohmann S, Morais P, et al. Immunogenicity risk assessment for nucleic acid therapeutics: a comprehensive evaluation for ASO, siRNA, and nonvaccine mRNA\/LNP therapies by the IQ Consortium. Nucleic Acid Ther. 2025;35(6):261\u201379.","journal-title":"Nucleic Acid Ther"},{"issue":"5","key":"1260_CR17","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1208\/s12248-022-00741-x","volume":"24","author":"N Bano","year":"2022","unstructured":"Bano N, Ehlinger C, Yang TY, Swanson M, Allen S. Considerations in the immunogenicity assessment strategy for oligonucleotide therapeutics (ONTs). AAPS J. 2022;24(5):93.","journal-title":"AAPS J"},{"issue":"3","key":"1260_CR18","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1208\/s12248-023-00796-4","volume":"25","author":"JR Mora","year":"2023","unstructured":"Mora JR, Richards SM. The AAPS Journal theme issue: compendium of immunogenicity risk assessments: an industry guidance built on experience and published work. AAPS J. 2023;25(3):43.","journal-title":"AAPS J"},{"key":"1260_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1581153","volume":"16","author":"J Grudzinska-Goebel","year":"2025","unstructured":"Grudzinska-Goebel J, Benstein K, Bloem K, Cowan KJ, Gorovits B, Jadhav M, et al. Immunogenicity risk assessment for tailored mitigation and monitoring of biotherapeutics during development: recommendations from the European Immunogenicity Platform. Front Immunol. 2025;16:1581153.","journal-title":"Front Immunol"},{"key":"1260_CR20","unstructured":"US Food and Drug Administration. Guidance for Industry Immunogenicity Assessment for Therapeutic Protein Products. 2014.\u00a0https:\/\/www.fda.gov\/media\/85017\/download.\u00a0Accessed 02 Jan 2026."},{"issue":"1","key":"1260_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-020-0207-x","volume":"5","author":"B Hu","year":"2020","unstructured":"Hu B, Zhong L, Weng Y, Peng L, Huang Y, Zhao Y, et al. Therapeutic siRNA: state of the art. Signal Transduct Target Ther. 2020;5(1):101.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"1260_CR22","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1186\/s12951-023-02147-z","volume":"21","author":"SS Ali Zaidi","year":"2023","unstructured":"Ali Zaidi SS, Fatima F, Ali Zaidi SA, Zhou D, Deng W, Liu S. Engineering siRNA therapeutics: challenges and strategies. J Nanobiotechnology. 2023;21(1):381.","journal-title":"J Nanobiotechnology"},{"issue":"2","key":"1260_CR23","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24020956","volume":"24","author":"IV Chernikov","year":"2023","unstructured":"Chernikov IV, Ponomareva UA, Chernolovskaya EL. Structural modifications of siRNA improve its performance in vivo. Int J Mol Sci. 2023;24(2):956.","journal-title":"Int J Mol Sci"},{"key":"1260_CR24","volume":"7","author":"J Wu","year":"2002","unstructured":"Wu J, Nantz MH, Zern MA. Targeting hepatocytes for drug and gene delivery: emerging novel approaches and applications. Front Biosci. 2002;7:d717-25.","journal-title":"Front Biosci"},{"issue":"10","key":"1260_CR25","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1038\/s41587-022-01334-x","volume":"40","author":"KM Brown","year":"2022","unstructured":"Brown KM, Nair JK, Janas MM, Anglero-Rodriguez YI, Dang LTH, Peng H, et al. Expanding RNAi therapeutics to extrahepatic tissues with lipophilic conjugates. Nat Biotechnol. 2022;40(10):1500\u20138.","journal-title":"Nat Biotechnol"},{"key":"1260_CR26","doi-asserted-by":"publisher","first-page":"7605","DOI":"10.2147\/IJN.S436038","volume":"18","author":"J Zhang","year":"2023","unstructured":"Zhang J, Chen B, Gan C, Sun H, Zhang J, Feng L. A comprehensive review of small interfering RNAs (siRNAs): mechanism, therapeutic targets, and delivery strategies for cancer therapy. Int J Nanomedicine. 2023;18:7605\u201335.","journal-title":"Int J Nanomedicine"},{"key":"1260_CR27","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/6262383","volume":"2016","author":"MA Partridge","year":"2016","unstructured":"Partridge MA, Purushothama S, Elango C, Lu Y. Emerging technologies and generic assays for the detection of anti-drug antibodies. J Immunol Res. 2016;2016:6262383.","journal-title":"J Immunol Res"},{"issue":"3","key":"1260_CR28","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1208\/s12248-024-00914-w","volume":"26","author":"KK Ballman","year":"2024","unstructured":"Ballman KK, Peek VL, Sloan JH, Li J, Konrad RJ, Wen Y. Cross-reactive polyclonal antibodies raised against GalNAc-conjugated siRNA recognize mostly the GalNAc moiety. AAPS J. 2024;26(3):41.","journal-title":"AAPS J"},{"issue":"3","key":"1260_CR29","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1038\/nrrheum.2013.4","volume":"9","author":"PA van Schouwenburg","year":"2013","unstructured":"van Schouwenburg PA, Rispens T, Wolbink GJ. Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis. Nat Rev Rheumatol. 2013;9(3):164\u201372.","journal-title":"Nat Rev Rheumatol"},{"issue":"5","key":"1260_CR30","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1111\/hae.12646","volume":"21","author":"SA Montalvao","year":"2015","unstructured":"Montalvao SA, Tucunduva AC, Siqueira LH, Sambo AL, Medina SS, Ozelo MC. A longitudinal evaluation of anti-FVIII antibodies demonstrated IgG4 subclass is mainly correlated with high-titre inhibitor in haemophilia A patients. Haemophilia. 2015;21(5):686\u201392.","journal-title":"Haemophilia"},{"issue":"1","key":"1260_CR31","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1007\/s10875-012-9792-y","volume":"33","author":"K Sch\u00fctz","year":"2013","unstructured":"Sch\u00fctz K, Hughes RG, Parker A, Quinti I, Thon V, Cavaliere M, et al. Kinetics of IgM and IgA antibody response to 23-valent pneumococcal polysaccharide vaccination in healthy subjects. J Clin Immunol. 2013;33(1):288\u201396.","journal-title":"J Clin Immunol"},{"key":"1260_CR32","unstructured":"US Food and Drug Administration. Immunogenicity testing of therapeutic protein products \u2014 developing and validating assays for anti-drug antibody detection. 2019.\u00a0https:\/\/www.fda.gov\/media\/119788\/download.\u00a0Accessed 02 Jan 2026."},{"key":"1260_CR33","unstructured":"Givosiran (GIVLAARI\u00ae) Highlights of Prescribing Information. 2019.\u00a0https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/0212194s000lbl.pdf.\u00a0Accessed 02 Jan 2026."},{"key":"1260_CR34","unstructured":"Inclisiran (LEQVIO\u00ae). Application 214012Orig1s000 Clinical Review. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2022\/214012Orig1s000MedR.pdf.\u00a0Accessed 02 Jan 2026."},{"key":"1260_CR35","unstructured":"Vutrisiran (AMVUTTRA\u00ae) Highlights of Prescribing Information. 2022. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/215515s000lbl.pdf.\u00a0Accessed 02 Jan 2026."},{"key":"1260_CR36","unstructured":"Fitusiran (QFITLIA\u2122). Highlights of prescribing information. 2025. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/219019s000lbl.pdf.\u00a0Accessed 02 Jan 2026."},{"key":"1260_CR37","unstructured":"Lumasiran (OXLUMO\u00ae) Highlights of Prescribing Information. 2025. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/214103s006lbl.pdf.\u00a0Accessed 02 Jan 2026."},{"key":"1260_CR38","unstructured":"Nedosiran (RIVFLOZATM\u2122) Highlight of Prescribing Information. 2025. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/215842s002lbl.pdf.\u00a0Accessed 02 Jan 2026."},{"key":"1260_CR39","unstructured":"Plozasoran (REDEMPLO\u00ae) Highlight of Prescribing Information. 2025. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/219947s000lbl.pdf.\u00a0Accessed 02 Jan 2026."},{"issue":"4","key":"1260_CR40","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1208\/s12248-022-00728-8","volume":"24","author":"M Starcevic Manning","year":"2022","unstructured":"Starcevic Manning M, Hassanein M, Partridge MA, Jawa V, Mora J, Ryman J, et al. Comparison of titer and signal to noise (S\/N) for determination of anti-drug antibody magnitude using clinical data from an industry consortium. AAPS J. 2022;24(4):81.","journal-title":"AAPS J"},{"issue":"17-18","key":"1260_CR41","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1080\/17576180.2024.2376949","volume":"16","author":"J Goodman","year":"2024","unstructured":"Goodman J, Cowan KJ, Golob M, Nelson R, Baltrukonis D, Bloem K, et al. Re-thinking the current paradigm for clinical immunogenicity assessment: an update from the discussion in the European Bioanalysis Forum. Bioanalysis. 2024;16(17\u201318):905\u201313.","journal-title":"Bioanalysis"},{"issue":"1","key":"1260_CR42","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1208\/s12248-024-00993-9","volume":"27","author":"CH Lai","year":"2024","unstructured":"Lai CH, Chen M, Fraser S, Wang J, McAfee S, Speaks E, et al. Challenging the standard immunogenicity assessment approach: 1-tiered ADA testing strategy in clinical trials. The AAPS Journal. 2024;27(1):11.","journal-title":"The AAPS Journal"},{"key":"1260_CR43","unstructured":"Givosiran (GIVLAARI\u00ae). Application 212194Orig1s000 Multi-Discipline Review. 2019. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2019\/212194Orig1s000Lbl.pdf.\u00a0Accessed 02 Jan 2026."},{"key":"1260_CR44","unstructured":"Lumasiran (OXLUMO\u00ae). Application 214103Orig1s000, Integrated review. 2020. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2020\/214103Orig1s000IntegratedR.pdf.\u00a0Accessed 02 Jan 2026."},{"key":"1260_CR45","unstructured":"Inclisiran (LEQVIO\u00ae). Application 214012Orig1s000 Clinical Review. 2022. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2022\/214012Orig1s000MedR.pdf.\u00a0Accessed 02 Jan 2026."},{"key":"1260_CR46","unstructured":"Vutrisiran (AMVUTTRA\u00ae). Application 215515Orig1s000, Clinical Reviews. 2022. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2022\/215515Orig1s000MedR.pdf.\u00a0Accessed 02 Jan 2026."},{"key":"1260_CR47","unstructured":"Nedosiran (RIVFLOZATM\u2122) 215842Orig1s000 Integrated Review. 2023. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2023\/215842Orig1s000IntegratedR.pdf.\u00a0Accessed 02 Jan 2026."},{"key":"1260_CR48","unstructured":"Mipomersen sodium (KYNAMRO) Highlight of Prescribing Information. 2013. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/203568s011lbl.pdf.\u00a0Accessed 02 Jan 2026."},{"key":"1260_CR49","unstructured":"Inotersen (TEGSEDI\u00ae), Highlight Prescribing Information. 2018. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/211172lbl.pdf.\u00a0Accessed 02 Jan 2026."},{"key":"1260_CR50","unstructured":"Volanesorsen (WAYLIVRA\u00ae). EMA Procedure No. EMEA\/H\/C\/004538\/0000 Assessment Report. https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/waylivra-epar-public-assessment-report_en.pdf.\u00a0Accessed 02 Jan 2026."},{"key":"1260_CR51","unstructured":"Tofersen (QALSODY\u00ae) Highlights Prescribing Information. 2023. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/215887s000lbl.pdf.\u00a0Accessed 02 Jan 2026."},{"key":"1260_CR52","unstructured":"Eplontersen (WEINUA\u2122). Highlights of Prescribing Information. 2023. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/217388s000lbl.pdf.\u00a0Accessed 02 Jan 2026."},{"key":"1260_CR53","unstructured":"Olezarsen (TRYNGOLZA\u2122). Highlights of prescribing information. 2024. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/218614s000lbl.pdf.\u00a0Accessed 02 Jan 2026."},{"issue":"3","key":"1260_CR54","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/s41577-018-0117-0","volume":"19","author":"SR Paludan","year":"2019","unstructured":"Paludan SR, Reinert LS, Hornung V. DNA-stimulated cell death: implications for host defence, inflammatory diseases and cancer. Nat Rev Immunol. 2019;19(3):141\u201353.","journal-title":"Nat Rev Immunol"},{"key":"1260_CR55","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1016\/j.omtn.2023.08.011","volume":"33","author":"AJ Pollak","year":"2023","unstructured":"Pollak AJ, Zhao L, Crooke ST. Characterization of cooperative PS-oligo activation of human TLR9. Mol Ther Nucleic Acids. 2023;33:832\u201344.","journal-title":"Mol Ther Nucleic Acids"},{"key":"1260_CR56","unstructured":"Casimersen (AMONDYS 45\u00ae). Application 213026Orig1s000 Other Review(s). 2021. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2021\/213026Orig1s000Approv.pdf.\u00a0Accessed 02 Jan 2026."},{"key":"1260_CR57","unstructured":"Defibrotide (DEFITELIO\u00ae). Application 208114Orig1s000 Summary Review. 2016. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2016\/208114Orig1s000SumR.pdf.\u00a0Accessed 02 Jan 2026."},{"key":"1260_CR58","unstructured":"Eteplirsen (EXONDYS 51\u00ae). NDA 206488 Accelerated Approval Letter. 2016. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/appletter\/2016\/206488orig1s000ltr.pdf.\u00a0Accessed 02 Jan 2026."},{"key":"1260_CR59","unstructured":"Golodirsen (Vyondys 53). Application 211970Orig1s000 Summary Review. 2019. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2019\/211970Orig1s000SumR.pdf.\u00a0Accessed 02 Jan 2026."}],"container-title":["The AAPS Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-026-01260-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1208\/s12248-026-01260-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-026-01260-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T18:08:36Z","timestamp":1785521316000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1208\/s12248-026-01260-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,19]]},"references-count":59,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["1260"],"URL":"https:\/\/doi.org\/10.1208\/s12248-026-01260-9","relation":{},"ISSN":["1550-7416"],"issn-type":[{"value":"1550-7416","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,19]]},"assertion":[{"value":"2 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original article has been updated to fix the formatting corrections.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors are employed by and receive compensation from their affiliations that are listed in this manuscript. The authors have no other relevant affiliations or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The views and conclusions presented in this paper are those of the authors and do not\u00a0necessarily reflects the representative\u2019s affiliation or company\u2019s position on the subject.","order":2,"name":"Ethics","label":"Disclaimer","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"106"}}